A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Resveratrol (Primary)
- Indications Gastrointestinal cancer
- Focus Pharmacodynamics
- 18 Nov 2019 Biomarkers information updated
- 12 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Apr 2013 Planned end date changed from 1 Oct 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.